Andrea Rubbert-Roth
Rheumatologie · Dept. I
Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
Ciurea A, Götschi A, Bräm R, Bürki K, Exer P, Andor M, Nissen M, Möller B, Hügle T, Rubbert-Roth A, Kyburz D, Distler O, Scherer A, Micheroli R. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry. RMD Open 2023; 9
01.12.2023Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry.
01.12.2023RMD Open 2023; 9
Ciurea Adrian, Götschi Andrea, Bräm René, Bürki Kristina, Exer Pascale, Andor Michael, Nissen Michael J, Möller Burkhard, Hügle Thomas, Rubbert-Roth Andrea, Kyburz Diego, Distler Oliver, Scherer Almut, Micheroli Raphael
Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
Rubbert-Roth A, Kakehasi A, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu S, Lippe R, Curtis J. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther 2023
20.11.2023Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
20.11.2023Rheumatol Ther 2023
Rubbert-Roth Andrea, Kakehasi Adriana M, Takeuchi Tsutomu, Schmalzing Marc, Palac Hannah, Coombs Derek, Liu Jianzhong, Anyanwu Samuel I, Lippe Ralph, Curtis Jeffrey R
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Spiera R, Unizony S, Warrington K, Sloane J, Giannelou A, Nivens M, Akinlade B, Wong W, Bhore R, Lin Y, Buttgereit F, Devauchelle-Pensec V, Rubbert-Roth A, Yancopoulos G, Marrache F, Patel N, Dasgupta B, SAPHYR Investigators. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. N Engl J Med 2023; 389:1263-1272.
05.10.2023Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
05.10.2023N Engl J Med 2023; 389:1263-1272
Spiera Robert F, Unizony Sebastian, Warrington Kenneth J, Sloane Jennifer, Giannelou Angeliki, Nivens Michael C, Akinlade Bolanle, Wong Wanling, Bhore Rafia, Lin Yong, Buttgereit Frank, Devauchelle-Pensec Valérie, Rubbert-Roth Andrea, Yancopoulos George D, Marrache Frederic, Patel Naimish, Dasgupta Bhaskar, SAPHYR Investigators
Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.
Finckh A, Ciurea A, Raptis C, Rubbert-Roth A. Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases. J Infect Dis 2023; 228:S13-S23.
04.08.2023Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.
04.08.2023J Infect Dis 2023; 228:S13-S23
Finckh Axel, Ciurea Adrian, Raptis Catherine E, Rubbert-Roth Andrea
Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry.
Micheroli R, Kissling S, Bürki K, Möller B, Finckh A, Nissen M, Exer P, Bräm R, Kyburz D, Rubbert-Roth A, Andor M, Baraliakos X, de Hooge M, Distler O, Scherer A, Ciurea A. Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry. Clin Rheumatol 2023; 42:2377-2385.
08.06.2023Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry.
08.06.2023Clin Rheumatol 2023; 42:2377-2385
Micheroli Raphael, Kissling Seraphina, Bürki Kristina, Möller Burkhard, Finckh Axel, Nissen Michael J, Exer Pascale, Bräm René, Kyburz Diego, Rubbert-Roth Andrea, Andor Michael, Baraliakos Xenofon, de Hooge Manouk, Distler Oliver, Scherer Almut, Ciurea Adrian
Methotrexate in rheumatoid arthritis-another brick in the wall.
Rubbert-Roth A. Methotrexate in rheumatoid arthritis-another brick in the wall. Lancet Rheumatol 2023; 5:e173-e175.
01.04.2023Methotrexate in rheumatoid arthritis-another brick in the wall.
01.04.2023Lancet Rheumatol 2023; 5:e173-e175
Rubbert-Roth Andrea
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
Taylor P, Chen Y, Pope J, Weinblatt M, Mysler E, Rubbert-Roth A, Jia B, Sun L, Liu Y, Holzkämper T, Tanaka Y. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies. Rheumatol Ther 2023; 10:463-476.
20.01.2023Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
20.01.2023Rheumatol Ther 2023; 10:463-476
Taylor Peter C, Chen Yun-Fei, Pope Janet E, Weinblatt Michael, Mysler Eduardo F, Rubbert-Roth Andrea, Jia Bochao, Sun Luna, Liu Yushi, Holzkämper Thorsten, Tanaka Yoshiya
Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
Amstad A, Papagiannoulis E, Scherer A, Rubbert-Roth A, Finckh A, Mueller R, Dudler J, Möller B, Villiger P, Schulz M, Kyburz D. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. Rheumatology (Oxford) 2022; 62:89-97.
23.12.2022Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
23.12.2022Rheumatology (Oxford) 2022; 62:89-97
Amstad Andrea, Papagiannoulis Eleftherios, Scherer Almut, Rubbert-Roth Andrea, Finckh Axel, Mueller Ruediger, Dudler Jean, Möller Burkhard, Villiger Peter M, Schulz Martin, Kyburz Diego
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
Koehm M, Foldenauer A, Rossmanith T, Alten R, Aringer M, Backhaus M, Burmester G, Feist E, Kellner H, Krueger K, Müller-Ladner U, Rubbert-Roth A, Tony H, Wassenberg S, Burkhardt H, Behrens F. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). J Clin Med 2022; 11
09.12.2022Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA).
09.12.2022J Clin Med 2022; 11
Koehm Michaela, Foldenauer Ann C, Rossmanith Tanja, Alten Rieke, Aringer Martin, Backhaus Marina, Burmester Gerd R, Feist Eugen, Kellner Herbert, Krueger Klaus, Müller-Ladner Ulf, Rubbert-Roth Andrea, Tony Hans-Peter, Wassenberg Siegfried, Burkhardt Harald, Behrens Frank
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen J, Landewé R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards C, Hyrich K, Pope J, de Souza S, Stamm T, Takeuchi T, Verschueren P, Winthrop K, Balsa A, Bathon J, Buch M, Burmester G, Buttgereit F, Cardiel M, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder A, El Aoufy K, Finckh A, Fonseca J, Gottenberg J, Haavardsholm E, Iagnocco A, Lauper K, Li Z, McInnes I, Mysler E, Nash P, Poór G, Ristic G, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland T, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2022
10.11.2022EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
10.11.2022Ann Rheum Dis 2022
Smolen Josef S, Landewé Robert B M, Bergstra Sytske Anne, Kerschbaumer Andreas, Sepriano Alexandre, Aletaha Daniel, Caporali Roberto, Edwards Christopher John, Hyrich Kimme L, Pope Janet E, de Souza Savia, Stamm Tanja, Takeuchi Tsutomu, Verschueren Patrick, Winthrop Kevin, Balsa Alejandro, Bathon Joan M, Buch Maya H, Burmester Gerd R, Buttgereit Frank, Cardiel Mario Humberto, Chatzidionysiou Katerina, Codreanu Catalin, Cutolo Maurizio, den Broeder Alfons A, El Aoufy Khadija, Finckh Axel, Fonseca João Eurico, Gottenberg Jacques-Eric, Haavardsholm Espen A, Iagnocco Annamaria, Lauper Kim, Li Zhanguo, McInnes Iain B, Mysler Eduardo F, Nash Peter, Poór Gyula, Ristic Gorica G, Rivellese Felice, Rubbert-Roth Andrea, Schulze-Koops Hendrik, Stoilov Nikolay, Strangfeld Anja, van der Helm-van Mil Annette, van Duuren Elsa, Vliet Vlieland Theodora P M, Westhovens René, van der Heijde Désirée
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
Raptis C, Berger C, Ciurea A, Andrey D, Polysopoulos C, Lescuyer P, Maletic T, Riek M, Scherer A, von Loga I, Safford J, Lauper K, Möller B, Vuilleumier N, Finckh A, Rubbert-Roth A. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Front Immunol 2022; 13:1016927.
13.10.2022Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases.
13.10.2022Front Immunol 2022; 13:1016927
Raptis Catherine E, Berger Christoph T, Ciurea Adrian, Andrey Diego O, Polysopoulos Christos, Lescuyer Pierre, Maletic Tanja, Riek Myriam, Scherer Almut, von Loga Isabell, Safford Judith, Lauper Kim, Möller Burkhard, Vuilleumier Nicolas, Finckh Axel, Rubbert-Roth Andrea
Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
Rubbert-Roth A, Furst D, Fiore S, Praestgaard A, Bykerk V, Bingham C, Charles-Schoeman C, Burmester G. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab. Arthritis Res Ther 2022; 24:207.
25.08.2022Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
25.08.2022Arthritis Res Ther 2022; 24:207
Rubbert-Roth Andrea, Furst Daniel E, Fiore Stefano, Praestgaard Amy, Bykerk Vivian, Bingham Clifton O, Charles-Schoeman Christina, Burmester Gerd R
[ORAL SURVEILLANCE: what has changed in the risk assessment of JAK inhibitors?].
Rubbert-Roth A. [ORAL SURVEILLANCE: what has changed in the risk assessment of JAK inhibitors?]. Z Rheumatol 2022; 81:780-781.
12.08.2022[ORAL SURVEILLANCE: what has changed in the risk assessment of JAK inhibitors?].
12.08.2022Z Rheumatol 2022; 81:780-781
Rubbert-Roth Andrea
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes I, Sattar N, Stamm T, Takeuchi T, Trauner M, van der Heijde D, Voshaar M, Winthrop K, Ravelli A, Betteridge N, Burmester G, Bijlsma J, Bykerk V, Caporali R, Choy E, Codreanu C, Combe B, Crow M, de Wit M, Emery P, Fleischmann R, Gabay C, Hetland M, Hyrich K, Iagnocco A, Isaacs J, Kremer J, Mariette X, Merkel P, Mysler E, Nash P, Nurmohamed M, Pavelka K, Poór G, Rubbert-Roth A, Schulze-Koops H, Strangfeld A, Tanaka Y, Smolen J. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis 2022
11.08.2022Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
11.08.2022Ann Rheum Dis 2022
Aletaha Daniel, Kerschbaumer Andreas, Kastrati Kastriot, Dejaco Christian, Dougados Maxime, McInnes Iain B, Sattar Naveed, Stamm Tanja, Takeuchi Tsutomu, Trauner Michael, van der Heijde Désirée, Voshaar Marieke, Winthrop Kevin, Ravelli Angelo, Betteridge Neil, Burmester Gerd-Rüdiger, Bijlsma Johannes Wj, Bykerk Vivian, Caporali Roberto, Choy Ernest H S, Codreanu Catalin, Combe Bernard, Crow Mary K, de Wit Maarten, Emery Paul, Fleischmann Roy, Gabay Cem, Hetland Merete Lund, Hyrich Kimme L, Iagnocco Annamaria, Isaacs John D, Kremer Joel M, Mariette Xavier, Merkel Peter A, Mysler Eduardo F, Nash Peter, Nurmohamed Michael T, Pavelka Karel, Poór Gyula, Rubbert-Roth Andrea, Schulze-Koops Hendrik, Strangfeld Anja, Tanaka Yoshiya, Smolen Josef S
Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma
Schmiedeberg K, Rassouli F, von Kempis J, Rubbert-Roth A. Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma. Rheumatology (Oxford) 2022
08.02.2022Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma
08.02.2022Rheumatology (Oxford) 2022
Schmiedeberg Kristin, Rassouli Frank, von Kempis Johannes, Rubbert-Roth Andrea
Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
Schmiedeberg K, Abela I, Pikor N, Vuilleumier N, Schwarzmueller M, Epp S, Pagano S, Grabherr S, Patterson A, Nussberger M, Trkola A, Ludewig B, von Kempis J, Rubbert-Roth A. Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. RMD Open 2022; 8
01.01.2022Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
01.01.2022RMD Open 2022; 8
Schmiedeberg Kristin, Abela Irene A, Pikor Natalia, Vuilleumier Nicolas, Schwarzmueller Magdalena, Epp Selina, Pagano Sabrina, Grabherr Sarah, Patterson Angelica Brooke, Nussberger Madalina, Trkola Alexandra, Ludewig Burkhard, von Kempis Johannes, Rubbert-Roth Andrea
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
Burmester G, Liu J, Mccaskill R, Lertratanakul A, Lippe R, Lesser E, Rubbert-Roth A, Salvarani C, Azevedo V, Goupille P, Nash P, Blanco R, Winthrop K, Ruderman E. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. Rheumatol Ther 2021
30.12.2021Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials
30.12.2021Rheumatol Ther 2021
Burmester Gerd R, Liu John, Mccaskill Reva M, Lertratanakul Apinya, Lippe Ralph, Lesser Elizabeth, Rubbert-Roth Andrea, Salvarani Carlo, Azevedo Valderilio F, Goupille Philippe, Nash Peter, Blanco Ricardo, Winthrop Kevin, Ruderman Eric M
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Rottländer Y, Pirker I, von Kempis J (2021). Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study.
28.12.2021Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
28.12.2021ACR Converence 2021
Rubbert-Roth Andrea, Vuilleumier Nicolas, Ludewig Burkhard, Schmiedeberg Kristin, Rottländer Yella, Pirker Ian, von Kempis Johannes
Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Rehberg M, Choy E, Rubbert-Roth A, Castañeda S, Schwarting A, Gottenberg J, Curtis J, Iglesias-Rodriguez M, van Hoogstraten H, Praestgaard A, Giegerich C, MOBILITY, MONARCH, TARGET, and ASCERTAIN investigators. Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. Rheumatol Ther 2021; 8:1921-1922.
01.12.2021Correction to: Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
01.12.2021Rheumatol Ther 2021; 8:1921-1922
Rehberg Markus, Choy Ernest H S, Rubbert-Roth Andrea, Castañeda Santos, Schwarting Andreas, Gottenberg Jacques-Eric, Curtis Jeffrey R, Iglesias-Rodriguez Melitza, van Hoogstraten Hubert, Praestgaard Amy, Giegerich Clemens, MOBILITY, MONARCH, TARGET, and ASCERTAIN investigators
Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?
Vuilleumier N, Pagano S, Ludewig B, Schmiedeberg K, Haller C, von Kempis J, Rubbert-Roth A. Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?. Eur J Clin Invest 2021; 52:e13713.
29.11.2021Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?
29.11.2021Eur J Clin Invest 2021; 52:e13713
Vuilleumier Nicolas, Pagano Sabrina, Ludewig Burkhard, Schmiedeberg Kristin, Haller Christoph, von Kempis Johannes, Rubbert-Roth Andrea